華東醫藥(000963.SZ):1.05億歐入股Heidelberg Pharma成二股東 並達成產品獨家許可協議
格隆匯2月28日丨華東醫藥(000963.SZ)公佈,公司與德國上市公司Heidelberg Pharma AG(簡稱“Heidelberg Pharma”)達成系列戰略合作協議:
(1)《股權投資協議》,公司通過全資子公司華東醫藥投資控股(香港)有限公司以6.44歐元/股的價格認購Heidelberg Pharma公開增發的股票並從交易對方收購部分股權,最終取得Heidelberg Pharma共計35%的股權,成為其第二大股東,股權投資金額1.05億歐元;
(2)《產品獨家許可協議》,公司全資子公司杭州中美華東製藥有限公司(簡稱“中美華東”)與Heidelberg Pharma達成產品獨家許可協議,中美華東獲得Heidelberg Pharma擁有的2款在研產品HDP-101、HDP-103在中國大陸、香港特別行政區、澳門特別行政區、台灣地區、韓國、新加坡等20個亞洲國家和地區(簡稱“許可區域”)的獨家許可,包括獨家開發及商業化權益。中美華東將向Heidelberg Pharma支付2000萬美元首付款,最高不超過4.49億美元的開發、註冊及銷售里程碑付款,以及從個位數到低兩位數的分級的淨銷售額提成費。
此外,中美華東還將獲得Heidelberg Pharma另外2款在研產品HDP-102、HDP-104的獨家選擇權(Opt-in),如中美華東對HDP-102,HDP-104行使了選擇權,每個產品將額外支付500萬美元一次性行權費、最高不超過2.255億美元的開發、註冊及銷售里程碑付款,以及從個位數到低兩位數的分級的淨銷售額提成費。
另外,根據合作協議,中美華東還擁有Heidelberg Pharma另外2款後續在研產品的優先談判權(ROFN)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.